HC Wainwright & Co. Reiterates Buy on Genmab, Maintains $51 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates a Buy rating on Genmab (NASDAQ:GMAB) and maintains a $51 price target.

June 06, 2023 | 10:24 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates a Buy rating on Genmab (NASDAQ:GMAB) and maintains a $51 price target.
The reiteration of a Buy rating and maintenance of a $51 price target by HC Wainwright & Co. analyst Raghuram Selvaraju indicates a positive outlook for Genmab's stock. This news is directly related to GMAB and is important for investors as it suggests potential upside in the stock price. The confidence in the analysis is high due to the analyst's expertise and the specific price target provided.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100